The short version of shelf life fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers |
| Typical storage temperature | -20 °C | Dry, desiccated, protected from light |
| Typical analytical method | RP-HPLC with UV detection | Often paired with LC-MS |
| Water content | Reported as Karl Fischer value | Freeze-dried material is hygroscopic |
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
== Adverse effects == The US Food and Drug Administration prescribing information contains a boxed warning for embryo-fetal toxicity. The most common adverse reactions include diarrhea, infusion-related reactions, abdominal pain, and fatigue.
== External links == tRNA, the Adaptor Hypothesis and the Wobble Hypothesis Wobble base-pairing between codons and anticodons Genetic Code and Amino Acid Translation Information of Aminoacyl tRNA Synthetases Genomic tRNA Database
=== Relative bioavailability === Relative bioavailability compares the bioavailability between two different dosage forms. Again, the relative AUCs are used to make this comparison and relative doses are used to normalize the calculation.
Sources: en.wikipedia.org
==== Medicare, Medicaid, and CHIP coverage ==== On 4 April 2025, the Trump administration declined to finalize a proposal from the Biden administration that would have required Medicare, Medicaid, and CHIP to broadly cover GLP-1s for weight loss. Despite the rejection, CMS has indicated that it might cover obesity medication in future rulemaking. But in November 2025, the Trump administration announced TrumpRx, an initiative similar to GoodRx to lower the price of GLP-1s to $245 per month for patients covered by Medicaid and CHIP and $50-month for Medicare patients if states opted in. Coverage for patients with obesity and at least one comorbidity like (elevated LDL-cholesterol, high blood pressure, or MASLD), will be implemented as early as 1 April 2026. The cost will be significantly higher to taxpayers since most health insurance companies do not cover it in their formulary. Before this change, most Medicaid and CHIP patients paid $3 a month, the same price as for brand-name medication. In December 2025, CMS announced the Medicare GLP-1 Bridge, a demonstration program running from 1 July to 31 December 2026, giving eligible Medicare Part D beneficiaries access to Wegovy and Zepbound at $50 per month. A longer-term program, the BALANCE Model, is planned for January 2027.
Cremasco, V., Woodruff, M. C., Onder, L., Cupovic, J., Nieves-Bonilla, J. M., Schildberg, F. A., Chang, J., Harvey, C. J., Wucherpfennig, B., Ludewig, B., Carroll, M. C., & Turley, S. J. (2014). B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nature Immunology, 15(8), 973–981. https://doi.org/10.1038/ni.2965 Li, L., Lu, Y., Zhou, L., Shi, S., Zhu, X., & Zhang, L. (2021). Lymph node fibroblastic reticular cells steer immune responses. Trends in Immunology. https://doi.org/10.1016/j.it.2021.06.002 Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007). Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naïve T cells. Nature Immunology, 8(11), 1255–1265. https://doi.org/10.1038/ni1513 Lütge, M., Pikor, N. B., & Ludewig, B. (2021). Differentiation and activation of fibroblastic reticular cells. Immunological Reviews, 302(1), 32–46. https://doi.org/10.1111/imr.12981 Mueller, S. N., & Germain, R. N. (2015). Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews Immunology, 15(12), 729–740. https://doi.org/10.1038/nri3846 Onder, L., Papadopoulou, C., Lütge, A., Cheng, H.-W., Lütge, M., Perez-Shibayama, C., Gil-Cruz, C., De Martin, A., Kurz, L., Cadosch, N., Pikor, N. B., Rodriguez, R., Born, D., Jochum, W., Leskow, P., Dutly, A., Robinson, M. D., & Ludewig, B. (2025). Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell, 188(2), 430–446.
The endogenous α-amino acids L-leucine and L-isoleucine, which resemble gabapentin in chemical structure, bind α2δ with similar affinity to gabapentin and are present in human cerebrospinal fluid at micromolar concentrations. They may be the endogenous ligands of the α2δ subunit, and they competitively antagonize the effects of gabapentin. Accordingly, while gabapentin has nanomolar affinity for the α2δ subunit, its potency in vivo is in the low micromolar range, and competition for binding by endogenous L-amino acids is likely to be responsible for this discrepancy. Gabapentin is a potent activator of voltage-gated potassium channels KCNQ3 and KCNQ5, even at low nanomolar concentrations. However, this activation is unlikely to be the dominant mechanism of gabapentin's therapeutic effects. Gabapentin is structurally similar to the neurotransmitter glutamate and competitively inhibits branched-chain amino acid aminotransferase (BCAT), slowing down the synthesis of glutamate. In particular, it inhibits BCAT-1 at high concentrations (Ki = 1 mM), but not BCAT-2. At very high concentrations, gabapentin can suppress the growth of cancer cells, presumably by affecting mitochondrial catabolism; however, the precise mechanism remains elusive. Even though gabapentin is a structural GABA analog, and despite its name, it does not bind to the GABA receptors, does not convert into GABATooltip γ-aminobutyric acid or another GABA receptor agonist in vivo, and does not modulate GABA transport or metabolism within the range of clinical dosing.
AThDP exists in small amounts in vertebrate liver, but its role remains unknown. AThTP is present in E. coli, where it accumulates as a result of carbon starvation. In this bacterium, AThTP may account for up to 20% of total thiamine. It also exists in lesser amounts in yeast, roots of higher plants and animal tissue.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.
Dry lyophilised powder is generally kept at minus twenty degrees Celsius, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they encourage aggregation and moisture uptake. Solutions are less stable than the solid form and degrade faster at room temperature.
A certificate documents what the supplier measured, not what an independent party confirmed. Methods, instruments and acceptance criteria can differ between suppliers. Third-party testing is the usual way to resolve discrepancies.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.